Indivior PLC announced on October 1, 2025, its intention to pursue a change in domicile from the U.K. to the U.S., establishing a new Delaware-based parent company, Indivior Pharmaceuticals, Inc. (IPI). This move follows Indivior's U.S. listing on Nasdaq in June 2023 and the subsequent cancellation of its secondary listing on the London Stock Exchange in July 2025.
The company's board of directors is recommending this proposed change to maximize the benefits of its U.S. stock listing. The redomiciliation will be implemented through a U.K. court-sanctioned scheme of arrangement.
Subject to shareholder approval, Indivior PLC will become a direct wholly owned subsidiary of IPI, and IPI's common stock will be listed on Nasdaq, continuing to trade under the symbol INDV. Shareholders of Indivior PLC will receive one new IPI share for each Indivior PLC share held.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.